“The most important news, in my opinion, from the point of view of the patient with multiple myeloma is that selinexor is an oral therapy which therefore allows the person not to have to be in hospital to be able to receive it”. These are the words of Felice Bombaci, coordinator national patient groups Ail – Italian Association against leukemia, lymphoma and myeloma, on the sidelines of the press conference organized in Milan by Menarini Stemline Italia to discuss the new perspectives in the treatment of multiple myeloma and blastic plasmacytoid dendritic cell neoplasia.
#Health #Bombaci #Ail #Oral #administration #selinexor #improves #patients #quality #life